Meningiomas comprise approximately 20% of adult primary intracranial neoplasms.
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Meningiomas along the medial sphenoid wing that invade the cavernous sinus are also a treatment challenge because of the possibility of tumor infiltration of the traversing cranial nerves and internal carotid artery and, to a lesser degree, the involvement of the adjacent pituitary gland. 22 The goal of surgical cure must therefore take into account local invasion of neurovascular structures within the cavernous sinus. As a consequence, several authors have emphasized the use of subtotal resection to limit the risk for permanent post-operative cranial nerve or the potential for vascular injury over complete resection. 7, 9, 12, 23 The long-term outcome after subtotal resection of meningiomas within the cavernous sinus alone is, however, associated with an unacceptably high symptomatic recurrence rate.
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Radiosurgical Treatment
Despite the high symptomatic recurrence rate and microsurgical improvements over the past few years, subtotal resection of meningiomas along the skull base, particularly those within the petroclival and cavernous sinus locations, remains a desired surgical outcome because such limited resection lends an acceptable level of morbidity. 7, 11, [25] [26] [27] Because of the unacceptable morbidity of radical resection, along with the high incidence of recurrence, adjuvant techniques for treating these tumors have been developed.
Early studies from the 1980s demonstrated that external-beam field radiation therapy could provide durable local tumor control for those benign meningiomas treated with subtotal resection through improved progression-free survival rates. [28] [29] [30] As more conformal therapies were developed, higher radiation doses could be administered while sparing dose to surrounding neural structures, resulting in an additional 31 have shown five-, 10-, and 15-year local control rates of 95, 92, and 92%, respectively, for meningiomas treated with radiation therapy subsequent to subtotal resection.
With the addition of 3D treatment planning, improvements in conformality have come about through the use of stereotactic radiosurgery (SRS) (single conformal treatment) and stereotactic radiotherapy (SRT) (fractionated conformal treatments). 32 SRS is useful in the treatment of meningiomas at locations in which surgery may cause damage to neurovascular structures, especially those involving the petroclivus region and cavernous sinus. 32 Fractionated SRT is more useful for those tumors that arise near critical structures such as the brainstem or optic chiasm. 32 The use of highly focused single-fraction radiation to irregular tumor volumes, along with steep dose gradients in radiosurgery, significantly protects adjacent critical structures from delayed radiation-induced injury.
SRS has become a popular alternative or adjuvant to resection in order to reduce the risk for tumor recurrence of skull base meningiomas. 25, [33] [34] [35] The efficacy of this method is clearly demonstrated by radiosurgical control rates, which have been reported to be extremely high: approaching or exceeding 90% in many contemporary studies involving either linear accelerator-based systems or gamma knife surgery (GKS). 2, 3, 25, 31, [36] [37] [38] [39] [40] [41] The efficacy of stereotatic radiosurgery as an alternative to aggressive resection was confirmed in a recent study published by Davidson et al. 42 They found that for those patients treated with GKS with an initial subtotal resection or with recurrent disease, the five-and 10-year actuarial progression-free survival rate was 100 and 94%, respectively.
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They state that the progression-free survival rate might have been 100%
had a single patient had her tumor growth area more adequately covered by the treatment plan.
Many have also considered radiosurgery to be an excellent stand-alone treatment of skull base meningiomas of less than 3cm. The caveat of such notable outcomes appears to be associated with the histological subtypes of the tumors. Stafford et al. 5 found that the five-year local control rate of meningiomas treated radiosurgically either primarily or subsequent to surgical treatment was 93, 68, and 0% in patients with benign, atypical, and malignant subtypes, respectively. Furthermore, the five-year cause-specific survival rate in patients with benign meningiomas was 100% compared with 83% in patients with atypical meningiomas and 0% in patients with a malignant meningioma after radiosurgery.
Despite reports documenting outstanding radiosurgical growth control rates (as an alternative to or part of a staged therapy with microsurgery), radiosurgical treatment fails in some cases, and little is known about the natural history of tumors that fail to stabilize after radiosurgery. There is very scant literature on the growth patterns of such tumors. 43 Couldwell et al. 43 have reported that aggressive regrowth of meningiomas can follow failed radiosurgery, even in a substantially delayed fashion (see Figure 1) . In several patients, meningiomas recurred several years after radiosurgical treatment (up to 14 years), indicating that consistent and extended followup evaluations should be performed in all cases of meningiomas, even benign meningiomas, after radiosurgery. Given this late regrowth potential, there is the distinct possibility of an increasing rate of treatment failure over time after radiosurgery. 43 In this analysis of failed radiosurgically treated meningiomas, tumor regrowth occurred both within and beyond the field of treatment.
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Conclusion
Gross total resection remains the preferred treatment for benign meningiomas that can be resected with reasonable morbidity and for Reported in a previous paper, the authors inactivated Nf2 in homozygous conditional knockout mice by adenoviral Cre delivery and demonstrated that Nf2 loss in arachnoid cells is rate-limiting for meningioma formation. In this paper, it is reported that additional nullizygosity for p16 Ink4a increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade. Also, through screening of a large cohort of mutant mice through magnetic resonance imaging, the authors were able to detect meningothelial proliferation and meningioma development. It is hoped that these findings will provoke future studies in which therapeutic interventions can be tested as pre-clinical assessment of their potential clinical application. ■
